Richard G. Moore

Also affiliated with University of Rochester

MedicinePsychology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile

0.208Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5522

Top 65%

0.208DataRank

Top 65%3 citations

Karen H. Lu, Deepak G. Bedi, Enrique Bedia, Therese B. Bevers, Laura L. Holman +16 more

Papers

Driven by 13 papers — median percentile 35. Top paper: “Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial”.

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.02011

N/A

2.6DataRank · unranked

88 citations

Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher +16 more

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.04.012

N/A

1.3DataRank · unranked

36 citations

José Alejandro Pérez Fidalgo, Bradley J. Monk, Ignacio Tusquets, Colleen McCormick, José Fuentes +20 more

A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07266-1

N/A

0.713DataRank · unranked

24 citations

Erin K. Campbell, Eva Culakova, Lisa Blanchard, Nellie Wixom, Joseph J. Guido +8 more

A whole food, plant-based randomized controlled trial in metastatic breast cancer: feasibility, nutrient, and patient-reported outcomes

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07284-z

N/A

0.550DataRank · unranked

17 citations

Thomas M. Campbell, Eva Culakova, Lisa Blanchard, Nellie Wixom, Joseph J. Guido +8 more

Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.03.009

N/A

0.473DataRank · unranked

7 citations

Bhavana Pothuri, Ana Oaknin, Whitney S. Graybill, Ana Beatriz Sánchez, Colleen McCormick +15 more

A Whole Food, Plant-Based Randomized Controlled Trial in Metastatic Breast Cancer: Feasibility, Nutrient, and Patient-Reported Outcomes

Research Square(2023)10.21203/rs.3.rs-3606685/v1

N/A

0.250DataRank · unranked

4 citations

Thomas M. Campbell, Eva Culakova, BS Lisa M. Blanchard, RD BS Nellie Wixom, MS Joseph Guido +8 more

The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5522

Top 65%

0.208DataRank

Top 65%3 citations

Karen H. Lu, Deepak G. Bedi, Enrique Bedia, Therese B. Bevers, Laura L. Holman +16 more

Stacking Machine Learning Algorithms for Biomarker-Based Preoperative Diagnosis of a Pelvic Mass

Cancers(2022)10.3390/cancers14051291

N/A

0DataRank · unranked

16 citations

Anna Lokshin, Michael Craig Miller, Geralyn Messerlian-Lambert, Richard G. Moore, Reid Shaw

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6003

N/A

0DataRank · unranked

56 citations

Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher +15 more

Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence

UNC Libraries(2020)10.17615/4pe6-bb70

N/A

0DataRank · unranked

2 citations

Kay J. Park, David G. Mutch, Shashikant B. Lele, Louise A. Brinton, Shamshad Ali +14 more

A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4618

N/A

0DataRank · unranked

21 citations

Virginia L. Filiaci, Joan L. Walker, Laura L. Holman, Emily K. Hill, Richard G. Moore +13 more

The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes

Scientific Reports(2020)10.1038/s41598-020-65353-x

N/A

0DataRank · unranked

37 citations

Jenna Emerson, Ashley Borgstadt, Lindsey Beffa, Matthew T. Oliver, Virginia Hovanesian +8 more

Vitamin D Receptor Antagonist MeTC7 Inhibits PD-L1

Cancers(2023)10.3390/cancers15133432

N/A

0DataRank · unranked

13 citations

Emily R. Quarato, Niloy A. Singh, Cameron Snyder, Taylor Moore, John Miller +34 more

Richard G. Moore

Indexed papers

Top data-sharing exemplar

Papers